H.6.Investigation: this statement is to summarize findings of a complaint against columbia cna agar with 5% sheep blood, catalog number 254072, lot number 0294956.Event description: it was reported that staph aureus would be discordant.Complaint history review: the complaints trends were reviewed.There were no similar complaints received during that period on this product lot.Therefore, a trend could not be identified.Batch history record (bhr) review: the batch history review did not indicate any discrepancies.All release testing was satisfactory, and no deviations were observed.Sample analysis: pictures were provided plates with growth.An analysis of growth promotion for the media was performed on retention samples for batch 0294956.The performance tests on retention samples of the above mentioned batch resulted in excellent growth of the following strains: str.Pyogenes atcc 19615, str.Pneumoniae atcc 6305, staph.Aureus atcc 25923, e.Faecalis atcc 29212, e.Coli atcc 25922.After an incubation time of 1 day at 36°c ± 1°c in co2 atmosphere.Evaluation results: at this stage of our investigation, we have excluded any systemic failure in our production process.No deviation could be found during the qc performance test.During this test, all strains referenced in the ifu were tested.However, lactobacillus was not referenced in the ifu.Investigation conclusion: based on the evaluation of the report and based on the qc test results, the complaint was not confirmed.A corrective and preventive action will not be implemented as a trend could not be identified.A definite root cause could not be determined.We would suggest that any prepared plated media be set aside and not use that does not meet the appearance specification as it is described on the bd certificate of analysis.This is consistent with industry recommendations for inspection of culture media prior to use (e.G.¿good practices for pharmaceutical microbiology laboratories¿, who technical report series, no.961, 2011, annex 2; chapter <1117> ¿microbiology best laboratory practices¿ the united states pharmacopeia; and the difco & bbl manual).H3 other text : see h.10.
|